Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 9/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556485 | 0.81 | GLA (0.53) | RXFP1TAS2R14MAPK8ABCG2MEN1 | |
| SCHEMBL22556309 | 0.80 | RAB9A (0.65) | RXFP1TAS2R14MAPK8ABCG2MEN1 | |
| SCHEMBL3670697 | 0.80 | SMN1; SMN2 (0.60) | HTTRAB9APTGS1SMN1; SMN2 | |
| SCHEMBL22556356 | 0.78 | RXFP1 (0.45) | RXFP1TAS2R14MAPK8ABCG2MEN1 | |
| SCHEMBL22571350 | 0.78 | RXFP1 (0.51) | RXFP1TAS2R14MAPK8ABCG2MEN1 | |
| SCHEMBL22556341 | 0.78 | RXFP1 (0.51) | RXFP1TAS2R14MAPK8ABCG2MEN1 | |
| SCHEMBL22556319 | 0.78 | RXFP1 (0.46) | RXFP1TAS2R14MAPK8ABCG2RAB9A | |
| SCHEMBL22556306 | 0.77 | RXFP1 (0.53) | RXFP1MAPK8ABCG2RAB9APTGS1 | |
| SCHEMBL22556326 | 0.77 | ALDH1A1 (0.54) | RXFP1TAS2R14MAPK8ABCG2MEN1 | |
| SCHEMBL22571408 | 0.77 | RXFP1 (0.50) | RXFP1TAS2R14MAPK8ABCG2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3793551-A1 | OXADIAZOLE COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885TAS2R14 4508/4885MAPK8 986/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885TAS2R14 4508/4885MAPK8 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.